Logo image of GLUE

MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis

NASDAQ:GLUE - Nasdaq - US61225M1027 - Common Stock - Currency: USD

5.03  -0.19 (-3.64%)

Fundamental Rating

3

Taking everything into account, GLUE scores 3 out of 10 in our fundamental rating. GLUE was compared to 568 industry peers in the Biotechnology industry. GLUE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLUE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

GLUE had negative earnings in the past year.
GLUE had a positive operating cash flow in the past year.
GLUE had negative earnings in each of the past 5 years.
In the past 5 years GLUE reported 4 times negative operating cash flow.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

GLUE's Return On Assets of -16.57% is amongst the best of the industry. GLUE outperforms 80.99% of its industry peers.
GLUE's Return On Equity of -32.61% is fine compared to the rest of the industry. GLUE outperforms 75.88% of its industry peers.
Industry RankSector Rank
ROA -16.57%
ROE -32.61%
ROIC N/A
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

GLUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

6

2. Health

2.1 Basic Checks

GLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
GLUE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GLUE has been increased compared to 5 years ago.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

GLUE has an Altman-Z score of -0.34. This is a bad value and indicates that GLUE is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -0.34, GLUE is doing good in the industry, outperforming 62.50% of the companies in the same industry.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -0.34
ROIC/WACCN/A
WACC10.3%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.40 indicates that GLUE has no problem at all paying its short term obligations.
The Current ratio of GLUE (2.40) is worse than 71.13% of its industry peers.
GLUE has a Quick Ratio of 2.40. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
GLUE has a Quick ratio of 2.40. This is in the lower half of the industry: GLUE underperforms 69.72% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.36% over the past year.
EPS 1Y (TTM)61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%139.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLUE will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.07% on average per year.
Based on estimates for the next years, GLUE will show a very strong growth in Revenue. The Revenue will grow by 25.00% on average per year.
EPS Next Y-49.6%
EPS Next 2Y-26.77%
EPS Next 3Y-10.38%
EPS Next 5Y-12.07%
Revenue Next Year158.24%
Revenue Next 2Y36.78%
Revenue Next 3Y54.05%
Revenue Next 5Y25%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

GLUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, GLUE is valued cheaply inside the industry as 98.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.14
EV/EBITDA N/A
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

GLUE's earnings are expected to decrease with -10.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.77%
EPS Next 3Y-10.38%

More info and screens

0

5. Dividend

5.1 Amount

GLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (4/25/2025, 3:41:59 PM)

5.03

-0.19 (-3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners102.4%
Inst Owner Change-0.07%
Ins Owners1.15%
Ins Owner Change-8.06%
Market Cap309.40M
Analysts84
Price Target17.05 (238.97%)
Short Float %11.56%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)560.97%
Min EPS beat(2)41.55%
Max EPS beat(2)1080.39%
EPS beat(4)4
Avg EPS beat(4)288.29%
Min EPS beat(4)9.3%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)136.9%
EPS beat(12)10
Avg EPS beat(12)91.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)376.36%
Min Revenue beat(2)244.78%
Max Revenue beat(2)507.93%
Revenue beat(4)3
Avg Revenue beat(4)242.11%
Min Revenue beat(4)-25.49%
Max Revenue beat(4)507.93%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.46%
PT rev (3m)4.46%
EPS NQ rev (1m)9.33%
EPS NQ rev (3m)4.8%
EPS NY rev (1m)3.17%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)470%
Revenue NQ rev (3m)470%
Revenue NY rev (1m)334.43%
Revenue NY rev (3m)334.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.09
P/FCF 8.14
P/OCF 7.37
P/B 1.39
P/tB 1.39
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)0.62
FCFY12.28%
OCF(TTM)0.68
OCFY13.57%
SpS1.23
BVpS3.62
TBVpS3.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.57%
ROE -32.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 50.26%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 49.11%
Cap/Sales 5.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z -0.34
F-Score6
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%139.66%
EPS Next Y-49.6%
EPS Next 2Y-26.77%
EPS Next 3Y-10.38%
EPS Next 5Y-12.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year158.24%
Revenue Next 2Y36.78%
Revenue Next 3Y54.05%
Revenue Next 5Y25%
EBIT growth 1Y43.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.07%
EBIT Next 3Y2.85%
EBIT Next 5YN/A
FCF growth 1Y160.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y195.88%
OCF growth 3YN/A
OCF growth 5YN/A